Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: A phase I-II trial

European Journal of Surgical Oncology

Volumn 30, Issue 6, 2004, Pages 671-680

  van IJken, M G A ^a   van Etten, B ^a   Guetens, G ^b   ten Hagen, T L M ^a   Jeekel, J ^a   de Bruijn, E A ^b   Eggermont, A M M ^a   van Eijck, C H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Abdomen; Balloon catheter; Celiac axis infusion; Hypoxic perfusion; Locally advanced; Melphalan; Mitomycin C; Pancreatic carcinoma; Phase I II; Stop flow

Indexed keywords

MELPHALAN; MITOMYCIN C; TUMOR MARKER;

ABDOMINAL RADIOGRAPHY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BALLOON CATHETER; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER PAIN; CANCER SURVIVAL; CAUSE OF DEATH; CELIAC ARTERY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FATALITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOXIA; INTERMETHOD COMPARISON; ISCHEMIA; LIVER TOXICITY; MALE; MESENTERIC ARTERY; NEUTROPENIA; PAIN ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGISTRATION; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

AGED; ANOXIA; ANTINEOPLASTIC AGENTS; BALLOON OCCLUSION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MELPHALAN; MIDDLE AGED; MITOMYCIN; PAIN; PAIN MEASUREMENT; PANCREATIC NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 4043101996     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.03.016     Document Type: Article

References (54)

1. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999 117 (6) 1463-84
2. Lim J.E. Chien M.W. Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients Ann Surg 237 1 2003 74-85
3. Bakkevold K.E. Arnesjo B. Kambestad B. Carcinoma of the pancreas and papilla of Vater-assessment of resectability and factors influencing resectability in stage I carcinomas. A prospective multicentre trial in 472 patients Eur J Surg Oncol 18 5 1992 494-507
4. Klinkenbijl J.H. Jeekel J. Schmitz P.I. Rombout P.A. Nix G.A. Bruining H.A. et al. Carcinoma of the pancreas and periampullary region: palliation versus cure Br J Surg 80 12 1993 1575-1578
5. DeVita V.H. Rosenberg S.A. In: Cancer of the pancreas (eds.) Cancer: principles and practise of oncology 1993 849-882 JB Lippincott Philadelphia
6. Geer R.J. Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 165 1 1993 68-72
7. Warshaw A.L. Fernandez-del Castillo C. Pancreatic carcinoma N Engl J Med 326 7 1992 455-465
8. Cameron J.L. Pitt H.A. Yeo C.J. Lillemoe K.D. Kaufman H.S. Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality Ann Surg 217(5) (430-5) 1993 435-438
9. Lillemoe K.D. Current management of pancreatic carcinoma Ann Surg 221 2 1995 133-148
10. Klinkenbijl J.H. Jeekel J. Sahmoud T. van Pel R. Couvreur M.L. Veenhof C.H. et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group Ann Surg 230(6) 6 1999 776-782
11. Morganti A.G. Valentini V. Macchia G. Alfieri S. Trodella L. Brizi M.G. et al. Adjuvant radiotherapy in resectable pancreatic carcinoma Eur J Surg Oncol 28 5 2002 523-530
12. Griffin J.F. Smalley S.R. Jewell W. Paradelo J.C. Reymond R.D. Hassanein R.E. et al. Patterns of failure after curative resection of pancreatic carcinoma Cancer 66 1 1990 56-61
13. Weiss L. Harlos J. Hartveld F. Metastasis pattern from cancers of the pancreas: an analysis of 558 autopsies Reg Cancer Treat 4 1992 265-271
14. Aigner K.R. Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis-rationale and technique Reg Cancer Treat 3 1993 6
15. Aigner K.R. Pelvic stopflow infusion and hypoxic pelvic perfusion-techniques and pharmacokinetics Reg Cancer Treat 1995 6
16. Aigner K.R. Gailhofer S. Celic axis infusion (MMC, CDDP,5-FU) and aortic stop-flow infusion vs abdominal hypoxic perfusion (MMC) in UICC stage III/IV pancreatic cancer-48 patients Reg Cancer Treat 6 3 1993
17. Aigner K.R. Kaevel K. Pelvic stopflow perfusion and hypoxic pelvic perfusion with MMC and melphalan for recurrent rectal cancer Reg Cancer Treat 7 1994 6-11
18. Guadagni S. Fiorentini G. Palumbo G. Valenti M. Russo F. Cantore M. et al. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer Arch Surg 136 1 2001 105-112
19. Chrysos E. Tsiaoussis J. Alexandra K. Athanasakis H. Tsetis D. Varveris C. et al. Treatment of unresectable malignant abdominal, pelvic and thoracic tumors using abdominal pelvic and thoracic stop-flow chemotherapy Anticancer Res 21 5 2001 3669-3675
20. Turk P.S. Belliveau J.F. Darnowski J.W. Weinberg M.C. Leenen L. Wanebo H.J. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique Arch Surg 128 5 1993 533-538
21. Lygidakis N.J. Sgourakis G. Aphinives P. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial Hepatogastroenterology 46 27 1999 2035-2038
22. Thompson J.F. Liu M. Watson L.D. Sheldon D.M. Stephan M.S. Storey D.W. et al. A percutaneous aortic stop-flow infusion technique for regional cytotoxic therapy of the abdomen and pelvis Reg Cancer Treat 7 1994 202-207
23. Aigner K.R. Regional chemotherapy-editorial review article Reg Canc Treat 2 1994 55-66
24. Fiorentini G. Poddie D. Ricci S. Intra-aorticstop-flow infusion with hypoxic abdominal perfusion in UICC stage III/IV pancreatic carcinoma: report of a phase II study Reg Cancer Treat 9 1996 88-91
25. Lorenz M. Petrowsky H. Heinrich S. Janshon G. Staib-Sebler E. Poloczek Y. et al. Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer Eur J Surg Oncol 24 6 1998 542-547
26. Gebauer T. Ridwelski K. Fahlke J. Lippet H. Locoregional and systemic therapy in advanced pancreatic carcinoma Arch Chir Suppl 2 1998 1344-1347
27. Lorenz M. Heinrich S. Staib-Sebler E. Kohne C.H. Wils J. Nordlinger B. et al. Regional chemotherapy in the treatment of advanced pancreatic cancer-is it relevant? Eur J Cancer 36 8 2000 957-965
28. Guadigni V.S. Lorenz M. Letter to the editor Eur J Surg Oncol 25 1999 339-340
29. WHO handbook for reporting results of cancer treatment. In: WHO Offset Publication no.48: WHO Offset; 1979.
30. Hofland J. Hofland J. van I.M.G. van Eijck C.H. Eggermont A.M. Erdmann W. Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy Br J Anaesth 88 2 2002 193-198
31. Tjaden U.R. de Bruijn E.A. Chromatographic analysis of anticancer drugs J Chromatogr 531 1990 235-294
32. de Boeck G. van Cauwenberghe K. Eggermont A.M. de Bruin E.A. Determination of melphalan and hydrolysis products in body fluids by GC-MS J High Res Chromatogr 20 1997 697-700
33. Ahlgren J.D. Chemotherapy for pancreatic carcinoma Cancer 78 Suppl 3 1996 654-663
34. el-Rayes B.F. Shields A.F. Vaitkevicius V. Philip P.A. Developments in the systemic therapy of pancreatic cancer Cancer Invest 21 1 2003 73-86
35. Kornmann M. Butzer U. Blatter J. Beger H.G. Link K.H. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer Eur J Surg Oncol 26 6 2000 583-587
36. Kuppen P.J. Schuitemaker H. van't Veer L.J. de Bruijn E.A. van Oosterom A.T. Schrier P.I. cis-Diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines Cancer Res 48 12 1988 3355-3359
37. Slee P.H. de Bruijn E.A. Leeflang P. Kuppen P.J. van den Berg L. van Oosterom A.T. Variations in exposure to mitomycin C in an in vitro colony-forming assay Br J Cancer 54 6 1986 951-955
38. Teicher B.A. Lazo J.S. Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells Cancer Res 41 1 1981 73-81
39. Vaupel P. Kallinowski F. Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review Cancer Res 49 23 1989 6449-6465
40. Christoforidis D. Martinet O. Lejeune F.J. Mosimann F. Isolated liver perfusion for non-resectable liver tumours: a review Eur J Surg Oncol 28 8 2002 875-890
41. Bartlett D.L. Libutti S.K. Figg W.D. Fraker D.L. Alexander H.R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer Surgery 129 2 2001 176-187
42. Marinelli A. Vahrmeijer A.L. van de Velde C.J. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases Recent Results Cancer Res 147 1998 83-94
43. Eggermont A.M. Schraffordt Koops H. Klausner J.M. Kroon B.B. Schlag P.M. Lienard D. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg 224 6 1996 756-764
44. Averbach A.M. Stuart O.A. Sugarbaker T.A. Stephens A.D. Fernandez-Trigo V. Shamsa F. et al. Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C J Surg Res 59 3 1995 415-419
45. Van IJken M.G.A. de Bruijn E.A. de Boeck G. ten Hagen T.L.M. van Eijck C.H.J. Eggermont A.M.M. Balloon catheter hypoxic abdominal and pelvic perfusion with tumor necrosis factor-alpha, Melphalan and MMC: a pharmacokinetic study in pigs. Eur J Surg Oncol [in press].
46. van IJken M.G.A. de Bruijn E.A. de Boeck G. ten Hagen T.L.M. van der Sijp J.R.M. Eggermont A.M.M. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs Ann Surg 228 6 1998 763-770
47. Averbach A.M. Stuart O.A. Sugarbaker T.A. Stephens A.D. Fernandez-Trigo V. Shamsa F. et al. Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers Ann Surg Oncol 2 4 1995 325-331
48. Averbach A.M. Sugarbaker T.A. Advanced gastric cancer: review of regional chemotherapy trials and treatment strategies using stop-flow infusion Reg Cancer Treat 8 1995 67-76
49. McGinn C.J. Lawrence T.S. Zalupski M.M. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer Cancer 95 4 2002 933-940
50. van der Schelling G.P. Jeekel J. Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile? World J Surg 23 9 1999 950-953
51. Link K.H. Gansauge F. Gorich J. Leder G.H. Rilinger N. Beger H.G. Palliative and adjuvant regional chemotherapy in pancreatic cancer Eur J Surg Oncol 23 5 1997 409-414
52. Klein E.S. Ben-Ari G.Y. Papa M.Z. Adar R. Bass A. Vascular complications of total abdominal perfusion and aortic stop-flow infusion J Surg Oncol 61 1 1996 17-19
53. Burris III H.A. Moore M.J. Andersen J. Green M.R. Rothenberg M.L. Modiano M.R. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403-2413
54. Neoptolemos J.P. Cunningham D. Friess H. Bassi C. Stocken D.D. Tait D.M. et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives Ann Oncol 14 5 2003 675-692